# Pilot Study to Assess Safety/Prelimary Effectiveness of Prefix in Subjects With Degenerative Disc Disease (DDD) Undergoing Spine Fusion Surgery

> **NCT00798239** · PHASE1,PHASE2 · UNKNOWN · sponsor: **BioSurface Engineering Technologies, Inc** · enrollment: 24 (estimated)

## Conditions studied

- Degenerative Disc Disease
- Spondylolisthesis

## Interventions

- **DEVICE:** Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
- **OTHER:** Iliac crest autograft
- **DEVICE:** Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules

## Key facts

- **NCT ID:** NCT00798239
- **Lead sponsor:** BioSurface Engineering Technologies, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-11
- **Primary completion:** 2012-05
- **Final completion:** 2012-07
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2012-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00798239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00798239, "Pilot Study to Assess Safety/Prelimary Effectiveness of Prefix in Subjects With Degenerative Disc Disease (DDD) Undergoing Spine Fusion Surgery". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00798239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*